Latest Information Update: 09 Mar 2017
At a glance
- Originator Takeda
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Crohn's disease
Most Recent Events
- 01 Feb 2017 Takeda terminates a phase I trial in Healthy volunteers in USA (PO, Liquid) (NCT02817516)
- 01 Jul 2016 Takeda initiates enrolment in a phase I trial for Crohn's disease (In volunteers) in USA (NCT02817516)
- 27 Jun 2016 Takeda plans a phase I trial in Healthy volunteers in USA (PO, Liquid) (NCT02817516)